LivaNova (NASDAQ:LIVN) Downgraded by StockNews.com to Hold

LivaNova (NASDAQ:LIVN - Get Free Report) was downgraded by investment analysts at StockNews.com from a "buy" rating to a "hold" rating in a research note issued on Wednesday.

A number of other equities research analysts have also recently weighed in on LIVN. Needham & Company LLC reiterated a "buy" rating and set a $72.00 price target on shares of LivaNova in a research report on Wednesday, March 20th. Robert W. Baird lifted their price target on shares of LivaNova from $56.00 to $62.00 and gave the company a "neutral" rating in a research report on Thursday, February 22nd. Barclays raised their price objective on shares of LivaNova from $57.00 to $61.00 and gave the company an "equal weight" rating in a research note on Monday, February 26th. Finally, Mizuho reissued a "buy" rating and issued a $75.00 price objective on shares of LivaNova in a research note on Wednesday, March 27th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, LivaNova currently has an average rating of "Hold" and a consensus price target of $64.40.

LivaNova Price Performance

Shares of NASDAQ:LIVN traded down $1.31 during midday trading on Wednesday, hitting $51.87. The company's stock had a trading volume of 484,959 shares, compared to its average volume of 610,994. The business's 50 day simple moving average is $53.51 and its 200 day simple moving average is $50.53. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.51 and a current ratio of 2.95. The company has a market cap of $2.80 billion, a P/E ratio of 162.10 and a beta of 0.89. LivaNova has a 12-month low of $42.75 and a 12-month high of $59.86.

LivaNova (NASDAQ:LIVN - Get Free Report) last posted its quarterly earnings results on Wednesday, February 21st. The company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.10. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The firm had revenue of $310.10 million for the quarter, compared to the consensus estimate of $287.65 million. During the same period last year, the firm posted $0.81 earnings per share. The company's revenue for the quarter was up 12.8% on a year-over-year basis. On average, analysts forecast that LivaNova will post 3.01 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in LIVN. Lazard Asset Management LLC acquired a new position in shares of LivaNova during the second quarter worth $46,000. Headlands Technologies LLC acquired a new stake in shares of LivaNova during the 3rd quarter worth about $72,000. Point72 Middle East FZE purchased a new stake in LivaNova during the fourth quarter worth approximately $72,000. Picton Mahoney Asset Management purchased a new stake in LivaNova during the third quarter worth approximately $91,000. Finally, PNC Financial Services Group Inc. lifted its stake in LivaNova by 16.7% during the second quarter. PNC Financial Services Group Inc. now owns 2,853 shares of the company's stock worth $147,000 after purchasing an additional 408 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.